Bacterin International, Inc. Enters into Eighth Amendment to the Amended and Restated Credit Agreement
January 20, 2017 at 04:30 pm EST
Share
Effective January 13, 2017, Bacterin International, Inc. (Bacterin) and wholly-owned subsidiary of Xtant Medical Holdings, Inc., as borrower, the company, X-Spine Systems, Inc. and wholly-owned subsidiary of the company, and Xtant Medical, Inc. and wholly-owned subsidiary of the company, collectively as the guarantors, ROS Acquisition Offshore LP (ROS) and OrbiMed Royalty Opportunities II, LP (OrbiMed), entered into the Eighth Amendment to Amended and Restated Credit Agreement, which amended the existing Amended and Restated Credit Agreement. The Facility generally provided for the refinancing of approximately $24,000,000 in previously existing term loans and the borrowing of an additional $18,000,000 by Bacterin.
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical Products, Thoracolumbar Products, Sacroiliac Joint Products, Interbody Products and Interlaminar Stabilization Products.
XTANT MEDICAL HOLDINGS, INC. 
